Gosset Ownership
Private
Employees
~25
Therapeutic Areas
Stage
Commercial
Preclinical
Phase 1
Phase 2
Phase 3
Approved
Modalities
Enteris BioPharma General Information
Ovarest® completed a Phase IIa trial with interim results reported. Tobrate™ received Fast Track and QIDP status from the FDA with Phase I safety completed. Multiple feasibility programs ongoing with pharma partners using proprietary oral peptide/small molecule delivery technologies.
Contact Information
Website
Primary Industry
Biotech
Corporate Office
Boonton, New Jersey
United States
United States
Drug Pipeline
No pipeline data available
Key Partnerships
Multiple undisclosed pharmaceutical partners for oral formulation development/licensing, blue-chip pharma clients referenced but not named publicly, Licensee(s) for TBRIA™ osteoporosis product noted.
Enteris BioPharma Funding
No funding data available
To view Enteris BioPharma's complete valuation and funding history, request access »